Speaker Profile
Ph.D., Chief Technology Officer, Enhanced Genomics
Biography
Dan has over 20 years of senior leadership experience within the fields of genetics, molecular biology and genomics research. He was previously Senior Vice President of Applications at Oxford Nanopore Technologies. During his time at Oxford Nanopore, he led the Applications function, which was responsible for developing the companys library preparation kits, protocols and analytical workflows, building collaborations with leading researchers, and enabling the commercial teams to bring the technology successfully to market. Dan also held the role of Head of Sequencing Technology Development at the Wellcome Trust Sanger Institute. He holds a degree in biochemistry from the University of Oxford and completed an MSc and PhD in genetics at the University of Manchester Institute of Science and Technology.
Talk
Illuminating the Dark Genome to Identify New Therapeutic Targets
Our proprietary 3D multiomics technology maps all disease-associated variants to genes, revealing 50% more potential drug targets for complex diseases. This gives us more targets to choose from and adds greater genetic validation to the targets we identify, reducing risk. We identify high confidence target genes 10x faster than traditional approaches.
AI for Emerging Therapeutics Showcase:
Enhanced Genomics
Enhanced Genomics is redefining drug target discovery by converting vast disease-associated genetic variant datasets into causal biology, delivering high-confidence, genetically validated drug targets for common diseases using a proprietary, cell-type-specific 3D multi-omics platform
Session Abstract – PMWC 2026 Silicon Valley
The PMWC 2026 AI for Emerging Therapeutics Showcase will provide a 15-30 minute time slot for selected companies to explore the transformative role of artificial intelligence in accelerating the discovery, development, and optimization of novel therapeutic modalities. From predictive algorithms for drug efficacy to real-time analysis in clinical trials, AI is revolutionizing the way we approach emerging therapies, including RNA-based treatments, gene editing, and personalized medicine. Industry leaders and experts will discuss AI-driven advancements, collaborative frameworks, and the challenges of integrating cutting-edge technologies into therapeutic innovation. Join us for an in-depth look at how AI is shaping the future of breakthrough therapeutics.
